Guardant Health Inc

Guardant Health insider buying by director Steve Krognes shows a steady confidence boost, with regular share purchases balanced by RSU sales, signaling long‑term belief in the company’s liquid‑biopsy technology.

Guardant Health insider sale: Tariq Musa sells 348 shares at $88.09—routine move that’s unlikely to shift stock price; investors see a neutral signal amid steady pipeline progress.

Guardant Health insider activity in March 2026 shows disciplined buying and selling that signals stable leadership confidence, with no immediate price‑driving moves.

Guardant Health Co‑CEO Helmy’s recent share sale shows routine liquidity use amid the company’s Asian expansion, underscoring steady insider confidence in Guardant’s growth strategy.

Guardant Health insider trades reveal a balanced liquidity strategy, showing co‑CEO AmirAli’s RSU‑driven buying amid routine sales—no confidence drop, just routine portfolio moves.

Guardant Health insider moves: CTO Darya Chudova buys 10,714 shares and sells 5,759 on March 15, 2026, signaling confidence in the company’s global expansion and product launches.

Guardant Health insider Tariq Musa’s recent 249‑share buy signals subtle confidence amid volatility, aligning with new Shield™ global launches and long‑term growth.

Guardant CFO’s insider buying signals confidence amid Asian expansion and Shield test growth—insight into future valuation and investor outlook.

Insider buying of Guardant Health shares shows confidence amid volatility: a strategic 264‑share purchase at $94.70 hints at upside potential as analysts lift targets, but earnings gaps warn of gradual growth.

Guardant Health insider buying signals cautious optimism amid earnings volatility—learn why small purchases matter for investors.